Real-World Treatment of Patients Newly Diagnosed with Chronic Obstructive Pulmonary Disease: A Retrospective German Claims Data Analysis

References

• França EB, Passos VMDA, Malta DC, et al. Cause-specific mortality for 249 causes in Brazil and states during 1990–2015: a systematic analysis for the global burden of disease study 2015. Popul Health Metr. 2017;15(1):39. doi:10.1186/s12963-017-0156-y
   PubMed Web of Science ®Google Scholar
• Soriano JB, Kendrick PJ, Paulson KR, et al. Prevalence and attributable health burden of chronic respiratory diseases, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet Respir Med. 2020;8(6):585–596. doi:10.1016/S2213-2600(20)30105-3
   PubMed Web of Science ®Google Scholar
• Rabe KF, Hurd S, Anzueto A, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med. 2007;176(6):532–555. doi:10.1164/rccm.200703-456SO
   PubMed Web of Science ®Google Scholar
• Søgaard M, Madsen M, Løkke A, Hilberg O, Sørensen HT, Thomsen RW. Incidence and outcomes of patients hospitalized with COPD exacerbation with and without pneumonia. Int J COPD. 2016;11(1):455–465. doi:10.2147/COPD.S96179
   Google Scholar
• Lindenauer PK, Dharmarajan K, Qin L, Lin Z, Gershon AS, Krumholz HM. Risk trajectories of readmission and death in the first year after hospitalization for chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2018;197(8):1009–1017. doi:10.1164/RCCM.201709-1852OC
   PubMed Web of Science ®Google Scholar
• Stöber A, Lutter JI, Schwarzkopf L, et al. Impact of lung function and exacerbations on health-related quality of life in COPD patients within one year: real-world analysis based on claims data. Int J Chron Obstruct Pulmon Dis. 2021;16:2637–2651. doi:10.2147/COPD.S313711
   PubMed Web of Science ®Google Scholar
• Menn P, Weber N, Holle R. Health-related quality of life in patients with severe COPD hospitalized for exacerbations - comparing EQ-5D, SF-12 and SGRQ. Health Qual Life Outcomes. 2010;8(1):39. doi:10.1186/1477-7525-8-39
   PubMed Web of Science ®Google Scholar
• Guo J, Chen Y, Zhang W, Tong S, Dong J. Moderate and severe exacerbations have a significant impact on health-related quality of life, utility, and lung function in patients with chronic obstructive pulmonary disease: a meta-analysis. Int J Surg. 2020;78:28–35. doi:10.1016/J.IJSU.2020.04.010
   PubMed Web of Science ®Google Scholar
• Esteban C, Quintana JM, Moraza J, et al. Impact of hospitalisations for exacerbations of COPD on health-related quality of life. Respir Med. 2009;103(8):1201–1208. doi:10.1016/J.RMED.2009.02.002
   PubMed Web of Science ®Google Scholar
• Lindenauer PK, Stefan MS, Shieh MS, Pekow PS, Rothberg MB, Hill NS. Hospital patterns of mechanical ventilation for patients with exacerbations of COPD. Ann Am Thorac Soc. 2015;12(3):402–409. doi:10.1513/ANNALSATS.201407-293OC
   PubMed Web of Science ®Google Scholar
• Lindenauer PK, Stefan MS, Shieh MS, Pekow PS, Rothberg MB, Hill NS. Outcomes associated with invasive and noninvasive ventilation among patients hospitalized with exacerbations of chronic obstructive pulmonary disease. JAMA Intern Med. 2014;174(12):1982–1993. doi:10.1001/JAMAINTERNMED.2014.5430
   PubMed Web of Science ®Google Scholar
• Singh D, Agusti A, Anzueto A, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive lung disease: the GOLD science committee report 2019. Eur Respir J. 2019;53(5):1900164. doi:10.1183/13993003.00164-2019
   PubMed Web of Science ®Google Scholar
• Global initiative for chronic obstructive lung disease (GOLD) guidelines; 2017. Available from: https://www.ajmc.com/view/global-initiative-for-chronic-obstructive-lung-disease-gold-guidelines-2017-update. Accessed November 22, 2021.
   Google Scholar
• Singh D. New combination bronchodilators for chronic obstructive pulmonary disease: current evidence and future perspectives. Br J Clin Pharmacol. 2015;79(5):695–708. doi:10.1111/bcp.12545
   PubMed Web of Science ®Google Scholar
• Lee CH, Kim K, Hyun MK, Jang EJ, Lee NR, Yim JJ. Use of inhaled corticosteroids and the risk of tuberculosis. Thorax. 2013;68(12):1105–1113. doi:10.1136/thoraxjnl-2012-203175
   PubMed Web of Science ®Google Scholar
• Ernst P, Saad N, Suissa S. Inhaled corticosteroids in COPD: the clinical evidence. Eur Respir J. 2015;45:525–537. doi:10.1183/09031936.00128914
   PubMed Web of Science ®Google Scholar
• Vogelmeier C, Buhl R, Burghuber O, et al. Guideline for the diagnosis and treatment of COPD patients: issued by the German respiratory society and the German atemwegsliga in cooperation with the Austrian society of pneumology. Pneumologie. 2018;72(4):253–308. doi:10.1055/s-0043-125031
   PubMed Web of Science ®Google Scholar
• Leung JM, Obeidat M, Sadatsafavi M, Sin DD. Introduction to precision medicine in COPD. Eur Respir J. 2019;53(4):1802460. doi:10.1183/13993003.02460-2018
   PubMed Web of Science ®Google Scholar
• GOLD 2017. Global initiative for chronic obstructive lung disease: pocket guide to COPD diagnosis, management, and prevention, A guide for health care professionals. Gold. 2017;1–33. doi:10.1097/00008483-200207000-00004
   Google Scholar
• Fricke U, Günther J, Nieprasch-von Dollen K, Zawinell A. Anatomisch-Therapeutisch-Chemische-Klassifikation Mit Tagesdosen Amtliche Fassung Des ATC-Index Mit DDD-Angaben Für Deutschland Im Jahre 2019. BMC Ecol. 2019. doi:10.1186/s12898-019-0245-9
   PubMed Web of Science ®Google Scholar
• Charlson M, Szatrowski TP, Peterson J, Gold J. Validation of a combined comorbidity index. J Clin Epidemiol. 1994;47(11):1245–1251. doi:10.1016/0895-4356(94)90129-5
   PubMed Web of Science ®Google Scholar
• Sundararajan V, Henderson T, Perry C, Muggivan A, Quan H, Ghali WA. New ICD-10 version of the Charlson comorbidity index predicted in-hospital mortality. J Clin Epidemiol. 2004;57(12):1288–1294. doi:10.1016/j.jclinepi.2004.03.012
   PubMed Web of Science ®Google Scholar
• Abholz HH, Gillissen A, Magnussen H, Schultz K, Ukena DWH. Nationale Versorgungsleitlinie COPD; 2012. Available from: http://www.copd.versorgungsleitlinien.de. Accessed November 22, 2021.
   Google Scholar
• Cardoso J, Ferreira AJ, Guimarães M, Oliveira AS, Simão P, Sucena M. Treatable traits in COPD – a proposed approach. Int J Chron Obstruct Pulmon Dis. 2021;16:3167–3182. doi:10.2147/COPD.S330817
   PubMed Web of Science ®Google Scholar
• Zatloukal J, Brat K, Neumannova K, et al. Chronic obstructive pulmonary disease – diagnosis and management of stable disease; a personalized approach to care, using the treatable traits concept based on clinical phenotypes. Position paper of the Czech pneumological and phthisiological society. Biomed Pap. 2020;164(4):325–356. doi:10.5507/BP.2020.056
   PubMed Web of Science ®Google Scholar
• Welte T, Vogelmeier C, Papi A. COPD: early diagnosis and treatment to slow disease progression. Int J Clin Pract. 2015;69(3):336–349. doi:10.1111/IJCP.12522
   PubMed Web of Science ®Google Scholar
• Brusselle G, Price D, Gruffydd-Jones K, et al. The inevitable drift to triple therapy in COPD: an analysis of prescribing pathways in the UK. Int J Chron Obstruct Pulmon Dis. 2015;10(1):2207. doi:10.2147/COPD.S91694
   PubMed Web of Science ®Google Scholar
• Miyazaki M, Nakamura H, Takahashi S, et al. The reasons for triple therapy in stable COPD patients in Japanese clinical practice. Int J Chron Obstruct Pulmon Dis. 2015;10:1053. doi:10.2147/COPD.S79864
   PubMed Web of Science ®Google Scholar
• Papala M, Kerenidi N, Gourgoulianis KI. Everyday clinical practice and its relationship to 2010 and 2011 GOLD guideline recommendations for the management of COPD. Prim Care Respir J J Gen Pract Airways Gr. 2013;22(3):362. doi:10.4104/PCRJ.2013.00073
   PubMedGoogle Scholar
• Corrado A, Rossi A. How far is real life from COPD therapy guidelines? An Italian observational study. Respir Med. 2012;106(7):989–997. doi:10.1016/J.RMED.2012.03.008
   PubMed Web of Science ®Google Scholar
• Burgel PR, Deslée G, Jebrak G, et al. Real-life use of inhaled corticosteroids in COPD patients versus the GOLD proposals: a paradigm shift in GOLD 2011? Eur Respir J. 2014;43(4):1201–1203. doi:10.1183/09031936.00162313
   PubMed Web of Science ®Google Scholar
• Lipson DA, Crim C, Criner GJ, et al. Reduction in all-cause mortality with fluticasone furoate/umeclidinium/vilanterol in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2020;201(12):1508–1516. doi:10.1164/RCCM.201911-2207OC/SUPPL_FILE/DISCLOSURES.PDF
   PubMed Web of Science ®Google Scholar
• Martinez FJ, Rabe KF, Ferguson GT, et al. Reduced all-cause mortality in the ETHOS trial of budesonide/glycopyrrolate/formoterol for chronic obstructive pulmonary disease a randomized, double-blind, multicenter, parallel-group study. Am J Respir Crit Care Med. 2021;203(5):553–564. doi:10.1164/RCCM.202006-2618OC/SUPPL_FILE/DISCLOSURES.PDF
   PubMed Web of Science ®Google Scholar
• Suissa S, Dell’aniello S, Ernst P. Triple inhaler versus dual bronchodilator therapy in COPD: real-world effectiveness on mortality. COPD. 2022;19(1):1–9. doi:10.1080/15412555.2021.1977789
   PubMedGoogle Scholar
• Miravitlles M, Verhamme K, Calverley PMA, et al. A pooled analysis of mortality in patients with COPD receiving dual bronchodilation with and without additional inhaled corticosteroid. Int J Chron Obstruct Pulmon Dis. 2022;17:545–558. doi:10.2147/COPD.S350167
   PubMed Web of Science ®Google Scholar
• Young D, Buhl R, Criée P, et al. A year in the life of German patients with COPD: the DACCORD observational study. Int J COPD. 2016;11(1):1639–1646. doi:10.2147/COPD.S112110
   Google Scholar
• Buhl R, Criée CP, Kardos P, et al. Dual bronchodilation vs triple therapy in the “real-life” COPD DACCORD study. Int J Chron Obstruct Pulmon Dis. 2018;13:2557. doi:10.2147/COPD.S169958
   PubMed Web of Science ®Google Scholar
• Quint JK, O’Leary C, Venerus A, et al. Prescribing pathways to triple therapy: a multi-country, retrospective observational study of adult patients with chronic obstructive pulmonary disease. Pulm Ther. 2020;6(2):333–350. doi:10.1007/s41030-020-00132-7
   PubMedGoogle Scholar
• Wacker ME, Jörres RA, Schulz H, et al. Direct and indirect costs of COPD and its comorbidities: results from the German COSYCONET study. Respir Med. 2016;111:39–46. doi:10.1016/j.rmed.2015.12.001
   PubMed Web of Science ®Google Scholar
• Darnell K, Dwivedi AK, Weng Z, Panos RJ. Disproportionate utilization of healthcare resources among veterans with COPD: a retrospective analysis of factors associated with COPD healthcare cost. Cost Eff Resour Alloc. 2013;11(1). doi:10.1186/1478-7547-11-13
   PubMedGoogle Scholar
• Wang Y, Stavem K, Dahl FA, Humerfelt S, Haugen T. Factors associated with a prolonged length of stay after acute exacerbation of chronic obstructive pulmonary disease (AECOPD). Int J COPD. 2014;9:99–105. doi:10.2147/COPD.S51467
   Google Scholar